Hormones may be leveraged to treat and prevent signs of aging such as wrinkles and hair graying, according to a new study.

Rigel Pharmaceuticals, Inc. RIGL is set to report its fourth-quarter and full-year 2024 earnings on March 4. The Zacks ...

GT Biopharma (GTBP) ended 2024 with roughly $4M in cash, enough to fund operations into the second quarter of 2025, Roth MKM tells investors in ...

Hormones may be leveraged to treat and prevent signs of aging such as wrinkles and hair graying, according to a study, ...

Phosphorylated tau 217 better detected Alzheimer’s disease pathology across a range of neurodegenerative syndromes compared ...

New research shows people in specific Polynesian communities have a much higher rate of a form of Parkinson’s disease ...

Shares of biotechnology company Rigel Pharmaceuticals, Inc. RIGL have surged 41.4% in the past year against the industry’s ...

Author:  Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of ...

A recent study from the University of Bologna has raised concerns about how beta-blockers, a common medication for high blood ...

Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

Researchers from the Mitochondrial Medicine Program at Children's Hospital of Philadelphia (CHOP) have better characterized a spectrum of what were classically considered discrete mitochondrial DNA ...

The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem ...